Vanguard Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $3.07B | Buy |
17,447,092
+157,857
| +0.9% | +$25.8M | 0.04% | 369 |
|
|
2025
Q3 | $2.42B | Sell |
17,289,235
-1,416
| -0% | -$191K | 0.04% | 430 |
|
|
2025
Q2 | $2.17B | Buy |
17,290,651
+257,812
| +2% | +$32.1M | 0.04% | 441 |
|
|
2025
Q1 | $2.33B | Buy |
17,032,839
+283,964
| +2% | +$40.6M | 0.04% | 409 |
|
|
2024
Q4 | $2.56B | Buy |
16,748,875
+70,368
| +0.4% | +$11.9M | 0.04% | 394 |
|
|
2024
Q3 | $3.23B | Buy |
16,678,507
+78,344
| +0.5% | +$16.4M | 0.06% | 327 |
|
|
2024
Q2 | $3.85B | Buy |
16,600,163
+29,765
| +0.2% | +$6.47M | 0.07% | 267 |
|
|
2024
Q1 | $3.57B | Buy |
16,570,398
+2,163,068
| +15% | +$507M | 0.07% | 288 |
|
|
2023
Q4 | $3.73B | Buy |
14,407,330
+2,218,744
| +18% | +$545M | 0.08% | 244 |
|
|
2023
Q3 | $3.13B | Sell |
12,188,586
-7,850
| -0.1% | -$2.1M | 0.08% | 257 |
|
|
2023
Q2 | $3.47B | Buy |
12,196,436
+38,774
| +0.3% | +$11.5M | 0.08% | 242 |
|
|
2023
Q1 | $3.38B | Buy |
12,157,662
+181,039
| +2% | +$50.1M | 0.09% | 250 |
|
|
2022
Q4 | $3.32B | Buy |
11,976,623
+61,650
| +0.5% | +$17.4M | 0.09% | 234 |
|
|
2022
Q3 | $3.18B | Buy |
11,914,973
+54,951
| +0.5% | +$11.7M | 0.09% | 223 |
|
|
2022
Q2 | $2.42B | Buy |
11,860,022
+139,438
| +1% | +$28.5M | 0.07% | 302 |
|
|
2022
Q1 | $2.47B | Buy |
11,720,584
+183,285
| +2% | +$39.9M | 0.06% | 358 |
|
|
2021
Q4 | $2.77B | Sell |
11,537,299
-154,577
| -1% | -$39.7M | 0.06% | 329 |
|
|
2021
Q3 | $3.31B | Sell |
11,691,876
-61,457
| -0.5% | -$20.1M | 0.08% | 247 |
|
|
2021
Q2 | $4.07B | Sell |
11,753,333
-100,325
| -0.8% | -$30.4M | 0.1% | 182 |
|
|
2021
Q1 | $3.32B | Sell |
11,853,658
-42,852
| -0.4% | -$11.6M | 0.09% | 212 |
|
|
2020
Q4 | $2.91B | Sell |
11,896,510
-451,562
| -4% | -$116M | 0.08% | 236 |
|
|
2020
Q3 | $3.5B | Sell |
12,348,072
-528,035
| -4% | -$147M | 0.12% | 155 |
|
|
2020
Q2 | $3.45B | Sell |
12,876,107
-1,362,120
| -10% | -$409M | 0.12% | 149 |
|
|
2020
Q1 | $4.5B | Buy |
14,238,227
+367,689
| +3% | +$112M | 0.19% | 98 |
|
|
2019
Q4 | $4.12B | Sell |
13,870,538
-224,988
| -2% | -$62.4M | 0.14% | 130 |
|
|
2019
Q3 | $3.28B | Sell |
14,095,526
-719,828
| -5% | -$168M | 0.12% | 168 |
|
|
2019
Q2 | $3.46B | Sell |
14,815,354
-200,117
| -1% | -$46.2M | 0.13% | 145 |
|
|
2019
Q1 | $3.55B | Sell |
15,015,471
-155,136
| -1% | -$48.9M | 0.14% | 138 |
|
|
2018
Q4 | $4.57B | Buy |
15,170,607
+356,482
| +2% | +$114M | 0.21% | 88 |
|
|
2018
Q3 | $5.23B | Sell |
14,814,125
-483,799
| -3% | -$167M | 0.2% | 84 |
|
|
2018
Q2 | $4.44B | Buy |
15,297,924
+168,681
| +1% | +$47.4M | 0.19% | 93 |
|
|
2018
Q1 | $4.14B | Buy |
15,129,243
+258,224
| +2% | +$80.2M | 0.18% | 100 |
|
|
2017
Q4 | $4.74B | Buy |
14,871,019
+202,077
| +1% | +$64.8M | 0.21% | 85 |
|
|
2017
Q3 | $4.59B | Buy |
14,668,942
+134,115
| +0.9% | +$39.7M | 0.21% | 83 |
|
|
2017
Q2 | $3.94B | Buy |
14,534,827
+182,337
| +1% | +$48.2M | 0.19% | 94 |
|
|
2017
Q1 | $3.92B | Buy |
14,352,490
+342,568
| +2% | +$96.9M | 0.2% | 87 |
|
|
2016
Q4 | $3.97B | Buy |
14,009,922
+163,866
| +1% | +$48.6M | 0.22% | 79 |
|
|
2016
Q3 | $4.33B | Buy |
13,846,056
+301,440
| +2% | +$89.3M | 0.25% | 65 |
|
|
2016
Q2 | $3.28B | Buy |
13,544,616
+182,714
| +1% | +$48.2M | 0.2% | 93 |
|
|
2016
Q1 | $3.48B | Buy |
13,361,902
+133,400
| +1% | +$35.2M | 0.23% | 80 |
|
|
2015
Q4 | $4.05B | Sell |
13,228,502
-349,032
| -3% | -$100M | 0.27% | 62 |
|
|
2015
Q3 | $3.96B | Buy |
13,577,534
+196,139
| +1% | +$64.8M | 0.29% | 59 |
|
|
2015
Q2 | $5.41B | Buy |
13,381,395
+239,059
| +2% | +$95.9M | 0.37% | 46 |
|
|
2015
Q1 | $5.55B | Buy |
13,142,336
+411,642
| +3% | +$162M | 0.38% | 46 |
|
|
2014
Q4 | $4.32B | Buy |
12,730,694
+395,460
| +3% | +$128M | 0.31% | 51 |
|
|
2014
Q3 | $4.08B | Buy |
12,335,234
+248,937
| +2% | +$82.1M | 0.32% | 50 |
|
|
2014
Q2 | $3.81B | Buy |
12,086,297
+187,167
| +2% | +$56.3M | 0.3% | 56 |
|
|
2014
Q1 | $3.64B | Buy |
11,899,130
+275,477
| +2% | +$87.4M | 0.31% | 52 |
|
|
2013
Q4 | $3.25B | Buy |
11,623,653
+105,771
| +0.9% | +$27.4M | 0.29% | 60 |
|
|
2013
Q3 | $2.77B | Buy |
11,517,882
+169,709
| +1% | +$38M | 0.27% | 67 |
|
|
2013
Q2 | $2.44B | Buy |
+11,348,173
| New | +$2.42B | 0.26% | 67 |
|
Other funds holding BIIB
Vanguard Group's BIIB Position: Q4 2025 in Review
Vanguard Group increased its Biogen (BIIB) stake by 0.91% in Q4 2025, buying an estimated $25.8M and bringing the position to 17,447,092 shares worth $3.07B. The position accounts for 0.04% of the portfolio, ranked #369.
Vanguard Group first reported a position in BIIB in Q2 2013 and has held it in 51 quarters since. The position peaked at $5.55B in Q1 2015. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.
- Vanguard Group held 17,447,092 shares of Biogen worth $3.07B as of Q4 2025.
- Vanguard Group bought 157,857 Biogen shares in Q4 2025, an estimated $25.8M.
- Biogen made up 0.04% of Vanguard Group's portfolio in Q4 2025, its #369 holding.
- Vanguard Group first reported a position in Biogen in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Biogen position peaked at $5.55B in Q1 2015.
- 1,001 funds tracked by Wall St. Rank held Biogen as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.